Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT06082167
Title Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (STELLAR-305)
Acronym STELLAR-305
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Exelixis
Age Groups: adult | senior
Covered Countries USA | ITA | FRA | BEL

No variant requirements are available.